कंपनी का अवलोकन
Nurix Therapeutics, Inc. operates as a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecule and antibody therapies designed to treat cancer, inflammatory conditions, and other diseases. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development phases before potential commercialization. As of the latest data, the entity maintains a market capitalization of $1.69B, generates annual revenue of $83.98M, and employs 317 individuals across its operations. These valuation and revenue figures indicate that Nurix Therapeutics holds a mid-sized position in the biotechnology landscape, reflecting significant investor capitalization relative to its current sales volume.
वित्तीय स्वास्थ्य
The company reported a revenue of $83.98M for the trailing twelve months, while recording a net income of $-264,456,992 and an EBITDA of $-277,526,016. The substantial negative gap between the positive revenue of $83.98M and the deep negative net income reveals a cost structure dominated by high operational expenses, likely driven by research, development, and administrative costs typical of clinical stage biotechnology firms. Free cash flow stands at $-143,989,248, indicating that the company is burning cash rapidly, which limits its immediate financial flexibility and reliance on external financing or cash reserves. The gross margin is reported at -277.4%, the operating margin at -612.0%, and the profit margin at 0.0%, suggesting that the current accounting framework or specific cost allocations are resulting in negative gross and operating profitability. Despite these negative margins, the company holds $592.94M in cash against $55.73M in debt, resulting in a debt-to-equity ratio of 10.34. This disparity between cash assets and liabilities suggests a balance sheet that is heavily leveraged by equity but liquid enough to service obligations if needed. The current ratio of 7.02 indicates a very strong short-term liquidity position, meaning the company possesses ample current assets to cover its short-term liabilities. Return on Equity is -49.6% and Return on Assets is -26.3%, metrics that reveal that management is currently generating negative returns on the capital invested and the assets utilized, consistent with the losses inherent in early-stage development phases.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -5.41, implying that the market anticipates continued negative earnings in the immediate future rather than a near-term profit turnaround. The price-to-book ratio stands at 3.09, indicating that the market values the company at a significant premium over its net book value, likely reflecting the intangible value of its intellectual property pipeline. The price-to-sales ratio is 20.13, and the EV/EBITDA is -4.12, suggesting that valuations for biotechnology firms often rely on revenue multiples or asset values rather than earnings when profitability is absent. The 52-week high is $22.50 and the 52-week low is $8.18, placing the current trading environment within a wide historical range that reflects significant market sentiment volatility. With a beta of 1.98, the stock exhibits high price volatility relative to the broader market, moving nearly twice as much as the overall index in response to market fluctuations.
Growth & Income
Revenue growth year-over-year is 2.2%, while earnings growth is N/A due to the company's negative net income position. The disparity between the modest revenue growth and the lack of earnings growth implies that top-line sales increases are not yet translating into profitability, a common characteristic of companies still in the clinical development phase. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available cash flow back into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by steady revenue expansion without earnings generation or dividend distribution, relying entirely on capital appreciation potential driven by future clinical trial outcomes.